Evidence map›Paper›PMID 42004968›Full record

ReviewFrontiers in immunology2026

Neuro-immune interactions in urticaria:a pruritus-centric dissection.

Chunxi Ke, Ni Ma, Gang Chen, Yuxu Yao, Jiang Ji, Qingqing Jiao

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chunxi KeDepartment of Dermatology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Ni MaDepartment of Dermatology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Gang ChenDepartment of Neurosurgery and Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, China.
Yuxu YaoDepartment of Dermatology, Affiliated Women's Hospital of Jiangnan University, Wuxi, China.
Jiang JiDepartment of Dermatology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Qingqing JiaoCentral Research Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Urticaria is a mast cell-driven skin disease, characterized by itchiness and transient wheal development. Although histamine released from activated mast cells is central to disease pathogenesis, increasing clinical evidence indicates that a subset of patients exhibit limited efficacy to antihistamines and biologics such as omalizumab. This therapeutic limitation emphasizes the involvement of additional, non-histaminergic pathways in disease persistence. Recent studies highlight the pivotal role of neuroimmune interactions, the crosstalk between the immune and nervous systems, especially in modulating type 2 inflammation and itch. In urticaria, neuroimmune mechanisms amplify pruritic signaling, and promote neurogenic inflammation, and sustain mast cell activation, collectively contributing to chronicity and treatment resistance. Deciphering these neuroimmune loops provides new insight into urticaria pathophysiology and identifies potential molecular targets for therapy. A growing number of biologics targeting neuroimmune pathways are showing encouraging efficacy in early clinical trials. This review adopts a pruritus-centered perspective to synthesize updated advances in neuroimmune research related to urticaria and to outline future directions for mechanism-based therapy.

Indexed as

NeuroimmunomodulationPruritusUrticariaAnimalsHumansMast CellsSignal Transductionitchneuroimmune interactionsneuropeptidetherapeutic targetsurticaria

Identifiers

PMID42004968
PMCPMC13083121

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.